Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Gilead Sciences, Inc.    GILD   US3755581036

GILEAD SCIENCES, INC. (GILD)

412
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

05/11/2012 | 03:06pm US/Eastern
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

React to this article
Latest news on GILEAD SCIENCES, INC.
05:01p GILEAD SCIENCES : to Present at the Cowen and Company 35th Annual Health Care Co..
12:43a GILEAD SCIENCES : Issues Preclinical Data for an Investigational TLR7 Agonist in..
02/27 IMMUNOVACCINE : TSX: IMV) receives Fast Track and Phase I trial approval for Ebo..
02/26 GILEAD SCIENCES : Announces Phase 3 Results for Investigational Once-Daily Singl..
02/26 GILEAD SCIENCES : Bristol-Myers: Drug combo cured hepatitis C in 97% with HIV
02/26 GILEAD SCIENCES : Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® f..
02/25 GILEAD SCIENCES : Patent Application Titled "Spray Dried Formulations" Published..
02/25 GILEAD SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
02/25 GILEAD SCIENCES : Announces Preclinical Data for an Investigational TLR7 Agonist..
02/24 GILEAD SCIENCES : to Present at the RBC Capital Markets 2015 Healthcare Conferen..
Advertisement
Chart
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF